Loading...
Developmental Therapeutics in Myeloproliferative Neoplasms
The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis provided much-needed impetus for clinical drug development for the Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The survival benefit conferred by this agent, along with its marked e...
Saved in:
| Published in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540010/ https://ncbi.nlm.nih.gov/pubmed/28760302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.02.014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|